Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + capecitabine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vorinostat + capecitabine is a combination therapy investigated for the treatment of advanced solid tumors. Vorinostat (also known as suberoylanilide hydroxamic acid or SAHA) is a small molecule histone deacetylase (HDAC) inhibitor that works by inhibiting Class I and II HDACs, thereby modulating gene expression to induce cell cycle arrest and apoptosis. Capecitabine is an oral fluoropyrimidine carbamate prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. 5-FU subsequently inhibits thymidylate synthase, disrupting DNA synthesis and cell proliferation. This specific combination was evaluated by the University Health Network in Toronto in a Phase I dose-escalation study to determine the safety and optimal dosing for patients with unresectable or metastatic solid tumors.
- Brand names
- ZolinzaXeloda
- Other names
- suberoylanilide hydroxamic acidN-hydroxy-N'-phenyloctanediamide
02
Targets
HDAC6 (Histone deacetylase 6)TS (Thymidylate synthase)HDAC1 (Histone Deacetylase 1)
Beyond the preview
Go deeper on vorinostat + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + capecitabine.